Adcendo inks MSD supply deal to run ADC-Keytruda combination study
Adcendo has struck a Keytruda supply agreement with MSD, positioning the Danish biotech to study an antibody-drug conjugate (ADC) with the blockbuster checkpoint inhibitor.
ADVERTISEMENT
New Search
If you are not happy with the results below please do another search
76 search results for: MSD
MSD Secures Option on EVX-B3
/in Latest NewsDanish Evaxion A/S hat optionally licenced its vaccine EVX-B3.developed with its AI-Immunology™ platform to Merck, Sharp & Dohme. MSD payed UIS$7.5m upfront and offers up to US$592m in milestone payments plus royalties on net sales.
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
/in Latest NewsUS pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones.
Curve Therapeutics in US$1.7bn deal with MSD
/in Latest NewsCurve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
BIOncoTech Therapeutics and MSD combine cancer drugs
/in Latest NewsMadrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary.
Noxxon/MSD start testing of immunoncologic combo
/in Latest NewsLast December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.
BerGenBio plans IPO and partners with MSD
/in Latest NewsNorwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor pembrolizumab in lung cancer patients.
Proteros inks US$167m oncology pact with MSD
/in Latest NewsProteros has expanded its epigenetic drug discovery services for MSD. Just one year after having signed a first R&D pact, the computational chemistry firm inked a second contract in oncology.
Leyden Labs adds €40m for intranasal flu prevention
/in Latest NewsDutch biotech Leyden Labs has raised €40m from a group of investors to advance its nasal spray approach for protection against influenza and other respiratory viruses.
OSE’s Tedopi-Keytruda combo clears Phase II ovarian cancer hurdle
/in Latest NewsFrench biotech OSE Immunotherapeutics has reported positive topline Phase II data for its cancer vaccine Tedopi in recurrent ovarian cancer, but the clinical signal is most clearly seen in combination with MSD’s anti-PD-1 antibody Keytruda.